Southern Shuanglin reports strong 2024, plans 3-for-10 stock split

Southern Shuanglin Bio-Pharmacy (SZSE:000403) reported robust 2024 results, driven by strong industry demand and increased plasma collection, while also unveiling plans for a 3-for-10 stock split and a CNY255.88 million cash dividend. Full-year revenue increased 14% to CNY2.65 billion, with net profit attributable to shareholders rising 21.76% to CNY745.32 million. Operational challenges included capacity constraints at its production facilities. Despite the strong year, cash flow from operations decreased by 52.61% to CNY321.79 million due to increased plasma procurement costs. To enhance shareholder returns, the company plans a cash dividend of CNY3.5 per 10 shares and a 3-for-10 stock split using capital reserves. In response to regulatory inquiries, Southern Shuanglin provided detailed justifications for the report. The company also announced personnel changes and updates to its operations. The organization expects to fully digest these developments and report a positive financial future.